Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Hunter Smith Sells 62,774 Shares of Stock

Posted by on Sep 2nd, 2026

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) CFO Hunter Smith sold 62,774 shares of Rhythm Pharmaceuticals stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $105.46, for a total value of $6,620,146.04. Following the transaction, the chief financial officer directly owned 114,024 shares in the company, valued at approximately $12,024,971.04. The trade was a 35.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Rhythm Pharmaceuticals Price Performance

RYTM opened at $104.74 on Wednesday. The firm has a market cap of $7.18 billion, a P/E ratio of -33.68 and a beta of 1.92. Rhythm Pharmaceuticals, Inc. has a 1-year low of $74.50 and a 1-year high of $122.20. The company has a 50 day simple moving average of $109.85 and a two-hundred day simple moving average of $96.97.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.08. The company had revenue of $71.25 million during the quarter, compared to the consensus estimate of $67.66 million. Rhythm Pharmaceuticals had a negative net margin of 85.59% and a negative return on equity of 159.87%. Rhythm Pharmaceuticals’s quarterly revenue was up 46.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.75) EPS. Equities analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -2.87 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on RYTM shares. Wells Fargo & Company raised their target price on shares of Rhythm Pharmaceuticals from $144.00 to $155.00 and gave the company an “overweight” rating in a report on Monday, June 15th. National Bank Financial set a $160.00 price target on shares of Rhythm Pharmaceuticals in a report on Wednesday, August 5th. Royal Bank Of Canada upped their price objective on Rhythm Pharmaceuticals from $141.00 to $155.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group set a $154.00 target price on Rhythm Pharmaceuticals in a research note on Wednesday, August 5th. Finally, JPMorgan Chase & Co. boosted their price objective on Rhythm Pharmaceuticals from $145.00 to $146.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Fifteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Rhythm Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $141.12.

Get Our Latest Stock Report on Rhythm Pharmaceuticals

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Several large investors have recently modified their holdings of the business. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Rhythm Pharmaceuticals during the second quarter valued at approximately $411,000. California State Teachers Retirement System lifted its holdings in Rhythm Pharmaceuticals by 10,703.5% during the second quarter. California State Teachers Retirement System now owns 7,109,362 shares of the company’s stock worth $789,352,000 after buying an additional 7,043,556 shares during the period. Braidwell LP boosted its position in Rhythm Pharmaceuticals by 22.7% during the 2nd quarter. Braidwell LP now owns 381,128 shares of the company’s stock valued at $42,317,000 after acquiring an additional 70,500 shares in the last quarter. Nykredit A S purchased a new position in shares of Rhythm Pharmaceuticals in the 2nd quarter valued at $280,000. Finally, Wellington Management Group LLP increased its holdings in shares of Rhythm Pharmaceuticals by 78.5% in the 2nd quarter. Wellington Management Group LLP now owns 488,747 shares of the company’s stock valued at $54,266,000 after acquiring an additional 214,990 shares during the period.

Rhythm Pharmaceuticals Company Profile

(Get Free Report)

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.

Featured Articles

Insider Buying and Selling by Quarter for Rhythm Pharmaceuticals (NASDAQ:RYTM)

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.